文献速递MDS 与骨髓增殖性肿瘤

普拉诺司他联合去甲基化药物治疗去甲基化药物无应答骨髓增生异常综合征的II期研究

A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.
PubMed 文献 · Br J Haematol · 2019-08-29

该II期研究评估在去甲基化药物(HMA)无应答的骨髓增生异常综合征(MDS)患者中加用普拉诺司他(pan-HDAC抑制剂)的疗效。

要点

  • 在HMA无应答MDS患者中加用普拉诺司他,临床改善率有限(CR 2%,骨髓CR 16%)。
  • ≥3级不良事件发生率达84%,33%患者因毒性停药,药物暴露不足。
  • 作者提出降低普拉诺司他剂量可能改善耐受性和疗效。

核心结论

  • 在既往接受HMA治疗的MDS患者中,加用普拉诺司他并未改善结局。
  • 频繁剂量调整和早期停药导致药物暴露不理想。

研究设计与样本

  • 患者接受普拉诺司他联合HMA治疗,中位3个周期。
  • 主要目标是评估临床改善率(CR、骨髓CR、PR和血液学改善)。

主要发现

  • 全部患者中,1例(2%)达CR,7例(16%)达骨髓CR,18例(40%)达SD,3例(7%)疾病进展。
  • 38例(84%)发生≥3级不良事件,12例(33%)因不良事件终止治疗。

临床怎么用

  • 对于HMA无应答的MDS患者,加用普拉诺司他未显示明确获益,且毒性显著。
  • 降低普拉诺司他剂量可能改善耐受性和疗效,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hypomethylating agents (HMAs) are standard of care for higher-risk myelodysplastic syndromes (MDS). However, less than half of patients achieve objective responses and most eventually lose their response. Pracinostat is a pan-histone deacetylase inhibitor with demonstrated activity in advanced myeloid malignancies. This phase II study explored the benefit of adding pracinostat to HMAs in MDS patients who did not respond to single-agent HMA treatment. The goal was to estimate the clinical improvement rate [complete remission (CR), marrow CR, partial response (PR) and haematological improvement]. Group 1 included patients with primary/secondary HMA failures; Group 2 included those who did not achieve response but had stable disease (SD) after single-agent HMAs. Forty-five patients (39 Group 1, 6 Group 2) received a median of 3 cycles. Among all patients, 1 (2%) had CR, 7 (16%) had marrow CR and 18 (40%) had SD; disease progression occurred in 3 (7%). Median overall survival was 5·7/5·6 months for Group 1/2. Grade ≥3 adverse events occurred in 38 patients (84%) leading to treatment discontinuation in 12 (33%). Adding pracinostat to HMAs did not improve outcomes in patients previously treated with HMAs. Frequent dose modifications/early discontinuation resulted in suboptimal drug exposure. A reduced pracinostat dose may improve tolerability and efficacy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Yalniz FF, Berdeja JG, Maris MB, et al. A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. Br J Haematol. 2019. PMID: 31468521. doi:10.1111/bjh.16173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。